- Home
- PRTA
as 03-06-2025 3:38pm EST
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 809.8M | IPO Year: | N/A |
| Target Price: | $54.57 | AVG Volume (30 days): | 373.0K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.70 - $30.86 | Next Earning Date: | 02-20-2025 |
| Revenue: | $135,157,000 | Revenue Growth: | 47.92% |
| Revenue Growth (this year): | -51.75% | Revenue Growth (next year): | 106.71% |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
Prothena Full Year 2024 Earnings: Misses Expectations
Zacks
13 days ago
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
MT Newswires
14 days ago
RBC Cuts Price Target on Prothena to $20 From $24, Keeps Sector Perform, Speculative Risk
GuruFocus.com
14 days ago
Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ...
Zacks
14 days ago
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
Associated Press Finance
14 days ago
Prothena: Q4 Earnings Snapshot
Business Wire
14 days ago
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
Business Wire
21 days ago
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.